VEA
MLYS icon

Virtus ETF Advisers’s Mineralys Therapeutics MLYS Stock Holding History

Virtus ETF Advisers’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-5,842
Closed -$71.9K – 643
2024
Q4 		$71.9K Sell
5,842
-1,425
-20% -$18.6K 0.03% 357
2024
Q3 		$88K Buy
7,267
+133
+2% +$1.61K 0.04% 394
2024
Q2 		$83.5K Sell
7,134
-3,367
-32% -$42.4K 0.04% 387
2024
Q1 		$136K Sell
10,501
-721
-6% -$8.9K 0.07% 339
2023
Q4 		$96.5K Buy
11,222
+5,017
+81% +$39.4K 0.06% 373
2023
Q3 		$59K Sell
6,205
-612
-9% -$7.98K 0.04% 405
2023
Q2 		$116K Buy
+6,817
New +$102K 0.07% 331

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Virtus ETF Advisers's MLYS Position: Q1 2025 in Review

Virtus ETF Advisers sold out of Mineralys Therapeutics (MLYS) in Q1 2025, closing a stake of 5,842 shares — an estimated $71.9K sold.

Virtus ETF Advisers first reported a position in MLYS in Q2 2023 and held it in 7 quarters. The position peaked at $136K in Q1 2024. 149 funds tracked by Wall St. Rank hold MLYS as of Q1 2025.

  • Virtus ETF Advisers reported no remaining Mineralys Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Virtus ETF Advisers sold 5,842 Mineralys Therapeutics shares in Q1 2025, an estimated $71.9K.
  • Virtus ETF Advisers first reported a position in Mineralys Therapeutics in Q2 2023 and held it in 7 quarters.
  • Virtus ETF Advisers's Mineralys Therapeutics position peaked at $136K in Q1 2024.
  • 149 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q1 2025.

Based on Virtus ETF Advisers's 13F filing for Q1 2025, filed 14 May 2025.